Clover Health Investments Corp
Ownership
Ownership Structure
Who owns Clover Health Investments Corp (CLOV)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 94.8% of the shares are freely tradable; institutional investors hold 30.0%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 5.99 | 31,840,512 | -1.4 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.20 | 16,982,073 | +0.0 | 03/31/2026 |
| Geode Capital Management, LLC | 1.89 | 10,055,510 | +2.7 | 03/31/2026 |
| State Street Corp | 1.80 | 9,559,889 | +2.6 | 03/31/2026 |
| Charles Schwab Investment Management Inc | 1.00 | 5,300,475 | +13.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 2.45 | 13,033,025 | +0.4 | 07/31/2026 |
| iShares Russell 2000 ETF | 2.06 | 10,955,731 | -0.6 | 08/31/2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 0.88 | 4,674,655 | +0.6 | 07/31/2026 |
| Fidelity Small Cap Index | 0.86 | 4,561,451 | +11.8 | 06/30/2026 |
| iShares Russell 2000 Growth ETF | 0.75 | 3,990,609 | +0.0 | 08/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Toy Andrew | Chief Executive Officer | 9,459,316 | 42,566,922 $ | Aug 10, 2026 | direct |
| Reynoso Jamie L. | CEO, Medicare Advantage | 2,805,367 | 12,624,152 $ | Sep 15, 2026 | direct |
| Wai Conrad | CEO, Counterpart Health | 2,315,755 | 10,420,898 $ | Jul 15, 2026 | both |
| Soares Karen | Chief Legal Officer | 1,607,371 | 7,233,170 $ | Sep 15, 2026 | direct |
| Thornton Joseph Clay | Interim CFO | 1,249,526 | 5,622,867 $ | Aug 17, 2026 | direct |
| Oldakowski Joseph Frank | VP OF FINANCE AND CONTROLLER | 279,067 | 1,255,802 $ | Sep 14, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Wai Conrad | CEO, Counterpart Health | Sell | 300,000 | 4.72 | 1,416,000 |
| Sep 15, 2026 | Soares Karen | Chief Legal Officer | Sell | 6,846 | 4.78 | 32,724 |
| Sep 15, 2026 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 9,273 | 4.78 | 44,325 |
| Sep 14, 2026 | Oldakowski Joseph Frank | VP OF FINANCE AND CONTROLLER | Sell | 20,000 | 5.16 | 103,200 |
| Aug 17, 2026 | Thornton Joseph Clay | Interim CFO | Sell | 17,775 | 4.39 | 78,032 |
| Aug 12, 2026 | Soares Karen | Chief Legal Officer | Other | 108,695 | 0.00 | – |
| Aug 12, 2026 | Thornton Joseph Clay | Interim CFO | Other | 54,347 | 0.00 | – |
| Aug 10, 2026 | Toy Andrew | Chief Executive Officer | Sell | 87,798 | 4.65 | 408,261 |
| Jul 20, 2026 | Soares Karen | Chief Legal Officer | Sell | 51,700 | 4.51 | 233,167 |
| Jul 17, 2026 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 4,839 | 4.53 | 21,921 |
| Jul 15, 2026 | Toy Andrew | Chief Executive Officer | Sell | 62,711 | 4.67 | 292,860 |
| Jul 15, 2026 | Wai Conrad | CEO, Counterpart Health | Sell | 24,215 | 4.67 | 113,084 |
| Jul 15, 2026 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 13,119 | 4.67 | 61,266 |
| Jul 15, 2026 | Soares Karen | Chief Legal Officer | Sell | 10,519 | 4.67 | 49,124 |
| Jul 15, 2026 | Thornton Joseph Clay | Interim CFO | Sell | 4,630 | 4.67 | 21,622 |
| Jul 8, 2026 | Reynoso Jamie L. | CEO, Medicare Advantage | Sell | 2,384 | 4.68 | 11,157 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.